Egis Pharmaceuticals PLC

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices.

Related News

BUSINESS INSIGHTS

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

news image

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More

PHARMACY MARKET

NOBEL BIOCARE RECEIVES FDA 510(K) CLEARANCE FOR THE NOBEL BIOCARE N1™ IMPLANT SYSTEM

Envista Holdings Corporation | December 28, 2021

news image

Envista Holdings Corporation announced that the U.S. Food and Drug Administration has cleared the Nobel Biocare N1™ implant system. Boasting a biologically driven design of components and forward-thinking treatment protocols, the N1™ implant system represents a significant step forward in patient-centric implant solutions. More than an implant, N1 is a comprehensive system of dedicated instruments, prosthetic components, and surgical protocols. New features of the syst...

Read More

CORONAVIRUS VACCINE: JOHNSON & JOHNSON PLEDGES 100M DOSES TO U.S. FOR $10 EACH

Johnson & Johnson | August 06, 2020

news image

With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. The pharma giant struck a deal to supply 100 million doses of its candidate, Ad26.COV2.S, if the shot is cleared for use by the FDA. The U.S. government is committing just over $1 billion under the agreement for a price per dose of about $10. That compares with a lower price-...

Read More

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More
news image

BUSINESS INSIGHTS

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More
news image

PHARMACY MARKET

NOBEL BIOCARE RECEIVES FDA 510(K) CLEARANCE FOR THE NOBEL BIOCARE N1™ IMPLANT SYSTEM

Envista Holdings Corporation | December 28, 2021

Envista Holdings Corporation announced that the U.S. Food and Drug Administration has cleared the Nobel Biocare N1™ implant system. Boasting a biologically driven design of components and forward-thinking treatment protocols, the N1™ implant system represents a significant step forward in patient-centric implant solutions. More than an implant, N1 is a comprehensive system of dedicated instruments, prosthetic components, and surgical protocols. New features of the syst...

Read More
news image

CORONAVIRUS VACCINE: JOHNSON & JOHNSON PLEDGES 100M DOSES TO U.S. FOR $10 EACH

Johnson & Johnson | August 06, 2020

With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. The pharma giant struck a deal to supply 100 million doses of its candidate, Ad26.COV2.S, if the shot is cleared for use by the FDA. The U.S. government is committing just over $1 billion under the agreement for a price per dose of about $10. That compares with a lower price-...

Read More
news image

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More